RVNC240517P7500
- 2.80
- 0.000.00%
Revance Therapeutics Newsroom
Revance Therapeutics Price Target Cut to $11.00/Share From $12.00 by HC Wainwright & Co.
Revance Therapeutics Price Target Cut to $11.00/Share From $12.00 by HC Wainwright & Co.
Revance Therapeutics Is Maintained at Neutral by Goldman Sachs
Revance Therapeutics Is Maintained at Neutral by Goldman Sachs
Express News | Goldman Sachs Maintains Neutral on Revance Therapeutics, Lowers Price Target to $8
Barclays Sticks to Its Buy Rating for Revance Therapeutics (RVNC)
Revance Therapeutics Reports Q1 2024 Financial Results: Revenue Growth Amidst Rising Operating ...
Revance Therapeutics Down Over 21%, on Pace for Largest Percent Decrease Since October 2021 -- Data Talk
Revance Therapeutics, Inc. (RVNC) is currently at $3.37, down $0.92 or 21.42% --Would be lowest close since April 25, 2024, when it closed at $3.29 --On pace for largest percent decrease since Oct.
NVAX, GRPN and MVIS Among Mid-day Movers
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Diodes posted adjusted earnings of 28 cents
12 Health Care Stocks Moving In Friday's Intraday Session
GainersNovavax (NASDAQ:NVAX) stock increased by 110.7% to $9.42 during Friday's regular session. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out to
Express News | Revance Therapeutics Shares Are Trading Lower Following Mixed Q1 Earnings
Earnings Call Summary | Revance Therapeutics(RVNC.US) Q1 2024 Earnings Conference
The following is a summary of the Revance Therapeutics Inc. (RVNC) Q1 2024 Earnings Call Transcript:Financial Performance:Q1 2024 revenue of $51.9 million reported, a 13% increase due to DAXXIFY.Net r
Piper Sandler Cuts Price Target on Revance Therapeutics to $11 From $20, Maintains Overweight Rating
Revance Therapeutics (RVNC) has an average outperform rating and price target range of $6 to $32, according to analysts polled by Capital IQ. Price: 3.26, Change: -1.04, Percent Change: -24.13
Novavax, Macrogenics, Biofrontera Among Healthcare Movers
These Analysts Lower Their Forecasts On Revance Therapeutics After Q1 Results
Revance Therapeutics, Inc. (NASDAQ:AKAM) posted a loss for its first quarter on Thursday.Revance Therapeutics posted a GAAP loss of 54 cents per share, compared to market expectations for a loss of 63
Express News | Mizuho Maintains Neutral on Revance Therapeutics, Lowers Price Target to $8
Piper Sandler Sticks to Its Buy Rating for Revance Therapeutics (RVNC)
Revance Therapeutics Is Maintained at Buy by Needham
Revance Therapeutics Is Maintained at Buy by Needham
Revance Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 172.73% Needham $18 → $12 Maintains Buy 03/01/2024 104.55% Goldman Sachs $8 → $9 Maintains Neut
Express News | Revance Therapeutics Inc : H.c. Wainwright Cuts Target Price to $11
Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Revance Therapeutics (RVNC) and CureVac (CVAC)